November 20, 2024
1 min watch
Save
VIDEO: Experts debate anatomic vs. functional benefits of therapies for dry AMD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this video, Karl G. Csaky, MD, PhD, discusses highlights from the AAO annual meeting.
In a panel discussion on dry age-related macular degeneration during the session Section XIV: Non-exudative AMD, experts debated the importance of anatomic vs. functional benefits of dry AMD therapies, according to Csaky, chief executive and medical officer of the Retina Foundation of the Southwest in Dallas.
Reference:
- Csaky K, et al. Section XIV: Non-exudative AMD. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Csaky reports consulting for AbbVie, Annexon Biosciences, Astellas, Boehringer Ingelheim Pharmaceuticals, Cognition Therapeutics, EyeBio, F. Hoffmann-La Roche AG, Genentech, Johnson & Johnson Health Care Systems, Merck, NGM Biopharmaceuticals, Novartis and Regeneron Pharmaceuticals and serving in a data and safety monitoring role for Adverum Biotechnologies.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.